Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of AGN 203818 for pain associated with fibromyalgia syndrome

Trial Profile

Safety and efficacy of AGN 203818 for pain associated with fibromyalgia syndrome

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2012

At a glance

  • Drugs Rezatomidine (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 May 2011 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified February 2009).
    • 23 Feb 2009 Planned end date changed from Jan 2010 to Apr 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top